JCR Pharmaceuticals Co., Ltd. (TYO:4552)
Japan · Delayed Price · Currency is JPY 682.00
+4.00 (0.59%)
Jan 22, 2026, 3:30 PM JST
JCR Pharmaceuticals Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| 37,777 | 33,072 | 42,871 | 34,343 | 51,082 | 30,085 | Upgrade | |
Revenue Growth (YoY) | 7.15% | -22.86% | 24.83% | -32.77% | 69.79% | 21.40% | Upgrade |
Cost of Revenue | 11,326 | 11,333 | 11,620 | 8,886 | 10,461 | 7,812 | Upgrade |
Gross Profit | 26,451 | 21,739 | 31,251 | 25,457 | 40,621 | 22,273 | Upgrade |
Selling, General & Admin | 14,551 | 12,958 | 12,485 | 11,678 | 13,511 | 8,643 | Upgrade |
Research & Development | 15,431 | 15,431 | 11,234 | 8,802 | 7,175 | 5,360 | Upgrade |
Operating Expenses | 30,152 | 28,580 | 23,719 | 20,480 | 20,686 | 13,984 | Upgrade |
Operating Income | -3,701 | -6,841 | 7,532 | 4,977 | 19,935 | 8,289 | Upgrade |
Interest Expense | -249 | -155 | -86 | -44 | -45 | -42 | Upgrade |
Interest & Investment Income | 121 | 147 | 137 | 61 | 35 | 32 | Upgrade |
Earnings From Equity Investments | -160 | -467 | -1,090 | - | - | - | Upgrade |
Currency Exchange Gain (Loss) | 366 | -196 | 767 | 387 | 551 | 206 | Upgrade |
Other Non Operating Income (Expenses) | 89 | 35 | 2 | 56 | 35 | 21 | Upgrade |
EBT Excluding Unusual Items | -3,534 | -7,477 | 7,262 | 5,437 | 20,511 | 8,506 | Upgrade |
Gain (Loss) on Sale of Investments | 250 | - | - | 10 | - | 22 | Upgrade |
Gain (Loss) on Sale of Assets | -33 | -2 | -20 | -36 | -2 | -5 | Upgrade |
Other Unusual Items | - | 1,065 | - | - | -1,106 | 129 | Upgrade |
Pretax Income | -3,317 | -6,414 | 7,242 | 5,411 | 19,403 | 8,652 | Upgrade |
Income Tax Expense | -1,009 | -1,718 | 1,707 | 1,625 | 4,886 | 1,764 | Upgrade |
Earnings From Continuing Operations | -2,308 | -4,696 | 5,535 | 3,786 | 14,517 | 6,888 | Upgrade |
Minority Interest in Earnings | -50 | -63 | -28 | -14 | -10 | 4 | Upgrade |
Net Income | -2,358 | -4,759 | 5,507 | 3,772 | 14,507 | 6,892 | Upgrade |
Net Income to Common | -2,358 | -4,759 | 5,507 | 3,772 | 14,507 | 6,892 | Upgrade |
Net Income Growth | - | - | 46.00% | -74.00% | 110.49% | 157.36% | Upgrade |
Shares Outstanding (Basic) | 122 | 124 | 125 | 124 | 124 | 124 | Upgrade |
Shares Outstanding (Diluted) | 122 | 124 | 125 | 125 | 124 | 124 | Upgrade |
Shares Change (YoY) | -2.11% | -1.25% | 0.45% | 0.51% | 0.06% | 0.07% | Upgrade |
EPS (Basic) | -19.29 | -38.43 | 44.13 | 30.34 | 117.26 | 55.80 | Upgrade |
EPS (Diluted) | -19.29 | -38.43 | 43.92 | 30.22 | 116.80 | 55.53 | Upgrade |
EPS Growth | - | - | 45.33% | -74.13% | 110.34% | 157.20% | Upgrade |
Free Cash Flow | -9,861 | -15,374 | 7,786 | -13,154 | -2,044 | 5,561 | Upgrade |
Free Cash Flow Per Share | -80.65 | -124.16 | 62.09 | -105.37 | -16.46 | 44.80 | Upgrade |
Dividend Per Share | 20.000 | 20.000 | 20.000 | 20.000 | 20.000 | 11.500 | Upgrade |
Dividend Growth | - | - | - | - | 73.91% | 43.75% | Upgrade |
Gross Margin | 70.02% | 65.73% | 72.89% | 74.13% | 79.52% | 74.03% | Upgrade |
Operating Margin | -9.80% | -20.69% | 17.57% | 14.49% | 39.02% | 27.55% | Upgrade |
Profit Margin | -6.24% | -14.39% | 12.85% | 10.98% | 28.40% | 22.91% | Upgrade |
Free Cash Flow Margin | -26.10% | -46.49% | 18.16% | -38.30% | -4.00% | 18.48% | Upgrade |
EBITDA | -535 | -3,467 | 10,729 | 6,974 | 21,880 | 10,181 | Upgrade |
EBITDA Margin | -1.42% | -10.48% | 25.03% | 20.31% | 42.83% | 33.84% | Upgrade |
D&A For EBITDA | 3,166 | 3,374 | 3,197 | 1,997 | 1,945 | 1,892 | Upgrade |
EBIT | -3,701 | -6,841 | 7,532 | 4,977 | 19,935 | 8,289 | Upgrade |
EBIT Margin | -9.80% | -20.69% | 17.57% | 14.49% | 39.02% | 27.55% | Upgrade |
Effective Tax Rate | - | - | 23.57% | 30.03% | 25.18% | 20.39% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.